BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26112923)

  • 1. Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer.
    Urbanska K; Stashwick C; Poussin M; Powell DJ
    Cancer Immunol Res; 2015 Oct; 3(10):1130-7. PubMed ID: 26112923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.
    Perales-Puchalt A; Svoronos N; Rutkowski MR; Allegrezza MJ; Tesone AJ; Payne KK; Wickramasinghe J; Nguyen JM; O'Brien SW; Gumireddy K; Huang Q; Cadungog MG; Connolly DC; Tchou J; Curiel TJ; Conejo-Garcia JR
    Clin Cancer Res; 2017 Jan; 23(2):441-453. PubMed ID: 27435394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive antitumor immunotherapy in vitro and in vivo using genetically activated erbB2-specific T cells.
    Wang C; Hu W; Shen L; Dou R; Zhao S; Shan D; Yu K; Huang R; Li H
    J Immunother; 2014 Sep; 37(7):351-9. PubMed ID: 25075564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.
    Klapdor R; Wang S; Hacker U; Büning H; Morgan M; Dörk T; Hillemanns P; Schambach A
    Hum Gene Ther; 2017 Oct; 28(10):886-896. PubMed ID: 28836469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered DNA Vaccination against Follicle-Stimulating Hormone Receptor Delays Ovarian Cancer Progression in Animal Models.
    Perales-Puchalt A; Wojtak K; Duperret EK; Yang X; Slager AM; Yan J; Muthumani K; Montaner LJ; Weiner DB
    Mol Ther; 2019 Feb; 27(2):314-325. PubMed ID: 30554854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
    Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD
    Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
    Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
    Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
    Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
    J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
    Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
    BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
    Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
    Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
    J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective Targeting of TAG72
    Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
    Front Immunol; 2018; 9():2268. PubMed ID: 30510550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.
    Tanaka H; Fujiwara H; Ochi F; Tanimoto K; Casey N; Okamoto S; Mineno J; Kuzushima K; Shiku H; Sugiyama T; Barrett AJ; Yasukawa M
    Clin Cancer Res; 2016 Sep; 22(17):4405-16. PubMed ID: 27091408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-specific T cells combine proliferation and antitumor activity.
    Kershaw MH; Westwood JA; Hwu P
    Nat Biotechnol; 2002 Dec; 20(12):1221-7. PubMed ID: 12415288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.
    Schutsky K; Song DG; Lynn R; Smith JB; Poussin M; Figini M; Zhao Y; Powell DJ
    Oncotarget; 2015 Oct; 6(30):28911-28. PubMed ID: 26359629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
    Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
    Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
    Ma Q; Gomes EM; Lo AS; Junghans RP
    Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
    Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
    Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes.
    Hong H; Stastny M; Brown C; Chang WC; Ostberg JR; Forman SJ; Jensen MC
    J Immunother; 2014; 37(2):93-104. PubMed ID: 24509172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Masked Chimeric Antigen Receptor for Tumor-Specific Activation.
    Han X; Bryson PD; Zhao Y; Cinay GE; Li S; Guo Y; Siriwon N; Wang P
    Mol Ther; 2017 Jan; 25(1):274-284. PubMed ID: 28129121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.